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Background: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in 
patients affected with late onset Stargardt disease (STGD).
Methods: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete 
ophthalmologic examination, including best-corrected visual acuity (BCVA) and multifocal 
electroretinogram (mfERG), was performed at inclusion day 0 (D0) and at month 6 (M6).
Results: Overall, no statistical differences have been observed at M6 vs D0 as regards BCVA 
and mfERG (P . 0.05). Mild Improvement of BCVA and improvement of mfERG was noted 
in seven/40 eyes of four/20 patients. In the first patient, the peak of the a wave increased from 
66 nV/deg² to 75.4 nV/deg² in the right eye (RE) and 24.5 nV/deg² to 49.1 nV/deg² in the 
left eye (LE). The peak of the b wave improved from 122 nV/deg² to 157 nV/deg² in the RE, 
and 102 nV/deg² to 149 nV/deg² in the LE. In the second patient peaks of the a and b waves 
  respectively increased from 11.8 nV/deg² to 72.1 nV/deg² and 53 nV/deg² to 185 nV/deg² in 
the RE. In the third patient the peak of the a wave increased from 37 nV/deg² to 43 nV/deg² in 
the RE, and from 31 nV/deg² to 45 nV/deg² in the LE; the peak of the b wave improved from 
70 nV/deg² to 89 nV/deg² in the RE, and from 101 nV/deg² to 108 nV/deg² in the LE. In the 
fourth patient, the peak of the a wave increased from 39 nV/deg² to 42 nV/deg² in the RE, and 
from 40 nV/deg² to 43 nV/deg² in the LE; the peak of the b wave improved from 86 nV/deg² to 
94 nV/deg² in the RE, and from 87 nV/deg² to 107 nV/deg² in the LE.
Conclusion: DHA seems to influence some functional parameters in patients affected with 
STGD. However, no short-term benefit should be expected from DHA supplementation.
Keywords: docosahexaenoic acid (DHA), multifocal electroretinogram, omega-3, 
  polyunsaturated fatty acid, retinal dystrophy, Stargardt disease
Background
Stargardt disease (STGD), described by Karl Stargardt in 1909,1–3 and fundus 
  flavimaculatus (FFM), a STGD-like phenotype described by Franceschetti in 19654 are 
variants of the same hereditary disease that affects the retinal pigment epithelium (RPE) 
and photoreceptor layer, both linked with the ABCA4 gene.5–7 When   characterized by 
a juvenile onset (first two decades), a rapidly progressive course, and a poor visual 
outcome, the disease is usually termed STGD. The term FFM is favored when the 
disease begins at the end of the second decade or within the third decade, and has a 
slowly progressive course.8–9 The general course of STGD and FFM is a progressive 
central atrophy, resulting in a central vision loss (#20/200). However, to date, the 
rapidity of visual loss remains unpredictable.10–11
The retina has a high concentration of omega-3, and particularly docosahexaenoic 
acid (DHA). The high concentration of DHA in the photoreceptors cells ( .50% of the 
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lipids of the external membrane) suggests its major role in 
the maintenance of the structure of these cells. Moreover, since 
photoreceptor outer segments require a constant   supply of these 
omega-3 fatty acids owing to their continuous renewal, diets 
rich in DHA may improve retinal function and slow-down the 
progressive photoreceptor degeneration. Many studies demon-
strated that DHA has a protective role in the retina,12–17 increased 
mitochondrial activity, increased RPE acid lipase activity, 
antioxidative, antiproliferative, and antiapoptotic effects.18
For these reasons, in this study, we decided to analyze the 
effects of DHA supplementation in patients affected with late 
onset STGD, an inherited macular dystrophy   characterized by 
progressive photoreceptor degeneration. The current study 
(NAT-3 study) is part of a clinical trial on nutritional   prevention 
treatment, that we have been   performing at our Department to 
study the preventive effects of DHA on   progression of age-
related macular degeneration (Nutritional AMD Treatment, 
NAT-1 and NAT-2 studies) and other macular diseases.
Methods
This study was designed as a prospective interventional pilot 
study. Patients diagnosed with late onset STGD (reported 
onset at .18 years old) were prospectively included. Informed 
consent was obtained according to a Paris XII University 
Institutional Review Board – approved protocol. Criteria 
for inclusion were: 1) age .18 years old; 2) evidence of 
  hypo-autofluorescence from areas of macular atrophy, 
associated or not with retinal flecks; 3) presence of hyper-
autofluorescent retinal flecks, associated or not with areas of 
macular atrophy, 4) diagnosis of dark choroid on fluorescein 
angiography (FA). This study was performed in agreement with 
the Declaration of Helsinki and French legislation, and was 
approved by our local ethics committee. In this trial DHA (840 
mg/day) was given to all patients for six months. A complete 
ophthalmologic examination including   best-corrected visual 
acuity (BCVA), measured at 4 m with standard Early Treatment 
Diabetic Retinopathy Study (ETDRS) charts,   fundus exami-
nation, autofluorescent frames (AF), FA, optical coherence 
tomography (OCT 3; Humphrey Zeiss, San Leandro, CA), 
and multifocal electroretinogram (mfERG), was performed 
at inclusion day 0 (D0) and at month 6 (M6).   Molecular biol-
ogy analysis of ELOVL4 gene was also   performed in order 
to establish   predicting factors of efficacy of DHA treatment. 
In addition, a complete profile of fatty acids in serum (S) 
and in red blood cell membranes (RBCM) performed by gas 
chromatography was recorded at D0 and M6.
Statistical calculations were performed using Epinfo 3.3 
software package (CDC, Atlanta, GA). The Mann–Whitney/
Wilcoxon two-sample test was used to compare main 
  ophthalmologic findings, and fatty acids in S and in RBCM, 
at D0 and M6. The chosen level of statistical significance 
was P , 0.05.
Results
Twenty unrelated patients (nine women, eleven men) with 
clinically definite late onset STGD were included (Table 1). 
Mean age of patients was 45 ± 15 years old (range 24–72). 
Neither side effects nor dropouts were observed in all patients. 
Overall, for the included patients, no statistical differences 
have been observed at M6 vs D0 as regards BCVA and 
mfERG (P . 0.05). Four out of the 20 patients showed a 
mild improvement of visual acuity (three eyes) and mfERG 
recordings (seven eyes). In the first patient (case three, a 
66 years old man), BCVA improved from 20/25 to 20/20 in 
the right eye (RE) and from 20/32 to 20/20 in the left eye 
(LE); the peak of the a wave increased from 66 nV/deg² to 
75.4 nV/deg² in the RE, and from 24.5 nV/deg² to 49.1 nV/deg² 
in the LE (Figure 1). The peak of the b wave improved from 
122 nV/deg² to 157 nV/deg² in the RE, and from 102 nV/deg² 
to 149 nV/deg² in the LE (Figure 1). In the second patient 
(case five, a 72 years old woman), BCVA improved from 
20/25 to 20/20 in the RE; the peak of the a wave increased 
Table 1 Patients demographics and BCVA changes from baseline 
to the six month FU
Case Gender Age BCVA at 
baseline 
BCVA at 
6-month FU
RE LE RE LE
case 1 M 57 20/50 20/40 20/50 20/40
case 2 F 30 20/125 20/40 20/125 20/40
case 3 M 66 20/25 20/32 20/20 20/20
case 4 M 51 20/40 20/160 20/40 20/160
case 5 F 72 20/25 20/40 20/20 20/40
case 6 M 55 20/32 20/50 20/32 20/50
case 7 F 24 20/20 20/20 20/20 20/20
case 8 F 49 20/100 20/80 20/100 20/80
case 9 M 41 20/40 20/50 20/40 20/50
case 10 M 39 20/25 20/32 20/25 20/32
case 11 M 25 20/32 20/32 20/32 20/32
case 12 F 62 20/64 20/50 20/64 20/50
case 13 M 36 20/100 20/200 20/100 20/200
case 14 M 30 20/50 20/160 20/50 20/160
case 15 M 34 20/64 20/25 20/64 20/25
case 16 F 46 20/20 20/25 20/20 20/25
case 17 F 62 20/64 20/64 20/64 20/64
case 18 F 48 20/32 20/50 20/32 20/50
case 19 F 51 20/25 20/25 20/25 20/25
case 20 M 26 20/32 20/40 20/32 20/40
Abbreviations:  BCVA,  best-corrected  visual  acuity;  FU,  follow-up;  M,  male;   
F, female; rE, right eye; LE, right eye.
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from 11.8 nV/deg² to 72.1 nV/deg² in the RE, and the peak 
of the b wave improved from 53 nV/deg² to 185 nV/deg² 
in the RE (Figure 2). The LE was affected with choroidal 
  neovascularization (CNV), and the patient was treated twice 
by   photodynamic therapy. No improvement was observed on 
BCVA and the foveal function. Nevertheless, it is notable that 
the four external rings slightly improved   (Figure 2). In the third 
patient (case seven, a 24 years old woman), BCVA was 20/20 
in both eyes at baseline, and remained unchanged throughout 
the six month period; the peak of the a wave increased from 
37 nV/deg² to 43 nV/deg² in the RE, and from 31 nV/deg² 
to 45 nV/deg² in the LE (Figure 3). The peak of the b wave 
improved from 70 nV/deg² to 89 nV/deg² in the RE, and from 
101 nV/deg² to 108 nV/deg² in the LE (Figure 3). In the fourth 
patient (case 11, a 25 years old man), BCVA was 20/32 in 
both eyes at baseline, and remained unchanged throughout 
the six-month period; the peak of the a wave increased from 
39 nV/deg² to 42 nV/deg² in the RE, and from 40 nV/deg² 
to 43 nV/deg² in the LE (Figure 4). The peak of the b wave 
improved from 86 nV/deg² to 94 nV/deg² in the RE, and from 
87 nV/deg² to 107 nV/deg² in the LE (Figure 4).
Figure 1 mfErG showing the peaks of a and b waves for case three. In the rE, the 
peak of the a wave increased from 66 nV/deg² (top left panel) to 75.4 nV/deg² (top 
right panel), and, in the LE, from 24.5 nV/deg² (bottom left panel) to 49.1 nV/deg² 
(bottom right panel), after six months. The peak of the b wave improved from 
122 nV/deg² (top left panel) to 157 nV/deg² (top right panel) rE, and from 102 nV/deg² 
(bottom left panel) to 149 nV/deg² (bottom right panel) LE, after six months.
Abbreviations: mfErG, multifocal electroretinogram; rE, right eye; LE, left eye.
Figure 2 mfErG showing the peaks of a and b waves for case five. In the RE the 
peaks of the a and b waves respectively increased from 11.8 nV/deg² (top right 
panel) to 72.1 nV/deg² (top left panel) and from 53 nV/deg² (top right panel) to 
185 nV/deg² (top left panel), after six months. The LE was affected with choroidal 
neovascularization: it is notable that the four external ring were improved when 
comparing before (bottom right panel) and after treatment (bottom left panel).
Abbreviations: mfErG, multifocal electroretinogram; rE, right eye; LE, left eye.
During this short period of time, no progression was 
observed in the size of the central atrophy. Moreover, FA 
revealed no progression to CNV in any of the 20 patients 
within the six month period. Molecular biology analysis of 
ELOVL4 gene which was performed to establish predicting 
factors of efficacy of DHA treatment, revealed the absence 
of ELOVL4 gene mutations in all patients. Five patients 
were explored for their plasma lipids before and after DHA 
supplementation. These patients showed significant changes, 
with a 106% increase in S DHA (1.5% at D0 vs up to 2.7% 
at M6, P = 0.013), and: a 37% increase in RBCM DHA 
(4.0% at D0 up to 5.2 at M6, P = 0.035). Other fatty acids 
were unchanged in S or RBCM.
There was no evidence of systemic illness or toxic effects 
attributable to DHA during the course of this study.
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Figure 4 Fundus autofluorescent frames (upper left and right panels) and mfERG for case 11. The peak of the a wave increased from 39 nV/deg² to 42 nV/deg² in the rE, 
and from 40 nV/deg² to 43 nV/deg² in the LE. The peak of the b wave improved from 86 nV/deg² (middle left panel) to 94 nV/deg² (middle left panel) in the rE, and from 
87 nV/deg² (middle right panel) to 107 nV/deg² (bottom right panel) in the LE.
Abbreviations: mfErG, multifocal electroretinogram; rE, right eye; LE, left eye.
Figure 3 Fundus autofluorescent frames (upper left and right panels) and mfERG for case seven. The peak of the a wave increased from 37 nV/deg² to 43 nV/deg² in the rE, 
and from 31 nV/deg² to 45 nV/deg² in the LE. The peak of the b wave improved from 70 nV/deg² (middle left panel) to 89 nV/deg² (bottom left panel) in the rE, and from 
101 nV/deg² (middle right panel) to 108 nV/deg² (bottom right panel) in the LE.
Abbreviations: mfErG, multifocal electroretinogram; rE, right eye; LE, left eye.
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Discussion
MacDonald et al19 recently demonstrated the efficacy of 
DHA in a 15 years old girl affected with autosomal dominant 
STGD macular dystrophy associated with the ELOVL4 gene 
mutation. ELOVL4 is homologous to a fatty acid elongase 
presumably involved in the biosynthesis of DHA. An animal 
study previously demonstrated that the dietary level of n-3 
fatty acids not only affects the level of DHA, but also the 
levels of very-long-chain fatty acids in rod outer segments 
(ROS) membranes.20 This young patient was given a dietary 
supplementation of DHA (20 mg/kg body weight/day) on 
two occasions, and a clear improvement was observed on 
visual function both subjectively (visual acuity, VF-14) and 
objectively (mfERG amplitudes). No conclusion can be 
drawn from one single case but this case report provides some 
hope for patients affected with STGD macular dystrophy 
associated with ELOVL4 mutations and a larger and longer 
study is warranted.
Hubbard et al21 investigated the influence of dietary fac-
tors on the phenotypic severity in a family with autosomal 
dominant STGD associated with ELOVL4 mutation. Red 
blood cell membrane and adipose tissue lipids were ana-
lyzed as an indication of short-term and long-term dietary 
fatty acid intake. The authors found a significant inverse 
relationship between phenotypic severity and levels of 
eicosapentaenoic acid and docosahexaenoic acid. These 
results indicate that the phenotypic diversity may be related 
to differences in dietary fat intake as reflected by adipose 
and red blood cell lipids.
In our series, molecular biology analysis of ELOVL4 
gene, which was performed in order to establish predicting 
factors of efficacy of DHA treatment, revealed the absence 
of ELOVL4 gene mutations in all the 20 patients. Despite 
this absence of ELOVL4 gene mutations (excluding that the 
direct disease-causing mechanism might be the ELOVL4 
gene involvement in fatty acid elongation in the retina), four 
out of 20 patients had an improvement of visual acuity and 
improvement of mfERG.
DHA is known to have specific retinal effects such as 
increased mitochondrial activity, increased RPE acid lipase 
activity, antioxidative, antiproliferative, and antiapoptotic 
effects.18 DHA has also shown to inhibit eicosanoid syn-
thesis from arachidonic acid and cytokine production form 
macrophages.22 This antiinflammatory effect could play a 
beneficial role in the retina as the pathway of inflammation 
is suggested to be involved in the occurrence of several 
retinal diseases. Moreover, since photoreceptor outer seg-
ments require a constant supply of these omega-3 fatty acids 
due to their continuous renewal (DHA represents the main 
component of the lipids of the external membrane of the 
photoreceptors cells, suggesting a major role in the main-
tenance of the structure of these cells), diets rich in DHA 
may improve retinal function and slow-down the progressive 
photoreceptor degeneration.
Of note, in our series, patients who had regular DHA 
intake during six months, and that were explored for their 
plasma lipids before and after DHA supplementation, 
displayed a strong and significant increase in serum and 
erythrocyte membrane DHA. Therefore, it may be that, 
DHA supplementation, mainly due to antiinflammatory, 
antioxidative and antiapoptotic properties,18 could have 
a protective effect in some cases of STGD whatever the 
genotype.
Mild improvement of BCVA and/or improvement of 
mfERG were noted in four/20 cases. Moreover, during this 
short period of time, no progression was observed either 
in the size of the central atrophy, or to CNV , in any of the 
20 patients. There was no evidence of systemic illness or a 
toxic effect that was attributable to DHA during the course 
of this study.
Our study is flawed by several shortcomings: the sample 
size was small, with no control group, and relatively short 
follow-up. No major improvement was observed in this 
series, given that only a mild effect was recorded, even 
on the four improved cases, we could not rule out normal 
inter-  examination variations of mfERG. Therefore, larger 
series and analysis of both ABCA4 and ELOVL4 genes is 
needed.
Conclusion 
DHA seems to influence some functional parameters in 
patients affected with STGD however, no short-term benefit 
should be expected from DHA supplementation.
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